-
- Michael R. Burgess
- Divisions of Hematology/Oncology, Department of Medicine and
-
- Eugene Hwang
- Department of Pediatrics, University of California San Francisco, San Francisco, CA;
-
- Ari J. Firestone
- Department of Pediatrics, University of California San Francisco, San Francisco, CA;
-
- Tannie Huang
- Department of Pediatrics, University of California San Francisco, San Francisco, CA;
-
- Jin Xu
- Department of Pediatrics, University of California San Francisco, San Francisco, CA;
-
- Johannes Zuber
- Research Institute of Molecular Pathology, Vienna, Austria;
-
- Natacha Bohin
- Department of Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI;
-
- Tiffany Wen
- Department of Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI;
-
- Scott C. Kogan
- Laboratory Medicine, University of California, San Francisco, San Francisco, CA;
-
- Kevin M. Haigis
- Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA;
-
- Deepak Sampath
- Department of Translational Oncology, Genentech Inc., South San Francisco, CA;
-
- Scott Lowe
- Howard Hughes Medical Institute;
-
- Kevin Shannon
- Department of Pediatrics, University of California San Francisco, San Francisco, CA;
-
- Qing Li
- Department of Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI;
書誌事項
- 公開日
- 2014-12-18
- DOI
-
- 10.1182/blood-2014-05-574582
- 公開者
- American Society of Hematology
この論文をさがす
説明
<jats:title>Key Points</jats:title> <jats:p>N-Ras expression is essential for the proliferative advantage of acute myeloid leukemias with oncogenic NRAS/Nras mutations. Mitogen-activated protein kinase kinase inhibition prolongs survival in Nras-mutant AML by reducing proliferation, but fails to undergo apoptosis.</jats:p>
収録刊行物
-
- Blood
-
Blood 124 (26), 3947-3955, 2014-12-18
American Society of Hematology
